The Effect of Abuse-Deterrent Extended-Release Oxycodone Leads to Inappropriate Conclusions with Over Estimation of Safety of Abuse-Deterrent Formulations

To The Editor:

Larochelle et al (1) published an original investigation on rates of opioid dispensing and overdose after the introduction of abuse-deterrent, extended-release oxycodone and the withdrawal of propoxyphene in the JAMA Internal Medicine. We believe that Larochelle et al may have misinterpreted the causes of opioid overdoses and the consequences of abuse-deterrent opioid formulations. These assumptions could lead readers to increase opioid prescriptions since abuse-deterrent, extended-release oxycodone is believed to be safe. In fact, overuse, abuse, and misuse of opioids have been a major issue of consideration for years, not only among some physicians, but also among regulators (2-5).

Opioid prescriptions for chronic noncancer pain skyrocketed in the late 1990s. Initially, this was the result of the lifting of opioid prescribing restrictions by state medical boards. A multitude of other factors then contributed to runaway opioid prescriptions. They include the implementation of pain management standards describing pain as the fifth vital sign by the Joint Commission on Accreditation of Health Care Organizations (4); the concept of a patient’s right to pain relief, resulting in validation of provider sensibilities towards increase opioid prescribing, and patients seeking more frequent, stronger opioids. Simultaneously, there were multiple organizations calling for opioid treatment for patients with chronic noncancer pain. Of concern, some of these organizations enjoyed material financial support from the pharmaceutical industry. (5).

Overall, an atmosphere has been created, though largely well intended, that justified increased opioid prescriptions based on a belief that opioid prescribing is necessary, safe, and effective as long as these medications are prescribed by a physician. We are writing this letter to the editor because it would appear that Larochelle et al seem to echo these misconceptions. To our knowledge there is no significant evidence that either short- or long- opioids, alone or in combination improve functional status when prescribed chronically for pain.

Various efforts to decrease opioid use include regulations, prescription monitoring programs, educating providers and patients, and abuse-deterrent formulations. Abuse-deterrent formulations alone, with limited distribution, will not prevent people receiving high-doses of opioids from overdosing. In fact, they may even increase them with patients believing they are safe with the same effect. Additionally, the disadvantage is that once patients are started on long-acting opioids, they will also be receiving short-acting opioids for breakthrough pain, thus increasing the overall use and dosages of opioids.

Laxmaiah Manchikanti, MD
Clinical Professor
Anesthesiology and Perioperative Medicine
University of Louisville
Louisville, Kentucky
Medical Director
Pain Management Center of Paducah
2831 Lone Oak Road
Paducah, KY 42003
E-mail: drlm@thepainmd.com

Sairam Atluri, MD
Medical Director
Tri-State Spine Care Institute
Cincinnati, Ohio
E-mail: saiatluri@gmail.com

Joshua A. Hirsch, MD
Vice Chair, Interventional Care
Service Line Chief
Interventional Radiology
Director
Endovascular and Interventional Neuroradiology
Chief, NeuroInterventional Spine Service
Co-Director, Neuroendovascular Program
Department of Radiology
Massachusetts General Hospital
Harvard Medical School.
E-mail: hirsch@snisonline.org
References


